Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Company Overview

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene. The company also markets Casgevy, a gene-editing therapy developed in collaboration with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia.

In addition to its cystic fibrosis and genetic-disease programs, Vertex develops treatments in areas including acute and chronic pain, kidney disease, and type 1 diabetes. Its non-opioid pain medicine, Journavx (suzetrigine), is designed to treat moderate to severe acute pain. Vertex serves patients and healthcare providers in the United States and international markets through its commercial operations and global research and development activities.

Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017. The company continues to invest in research aimed at developing medicines that address the underlying biology of disease rather than primarily managing symptoms.

Key Stats

• Today's Range: $497.49 to $512.21
• 50-Day Range: $485.22 to $557.96
• 52-Week Range: $403.16 to $560.25
• Volume: 1.41 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $126.83 billion
• P/E Ratio: 29.36
• Dividend Yield: N/A
• Price Target: $579.81
• Consensus Rating: Moderate Buy

Vertex Pharmaceuticals Stock Analysis - MarketRank™

Vertex Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 93rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 24 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Vertex Pharmaceuticals has a consensus price target of $579.81, representing about 16.0% upside from its current price of $499.74.

Amount of Analyst Coverage

Vertex Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.16%

Earnings Growth

Earnings for Vertex Pharmaceuticals are expected to grow by 10.16% in the coming year, from $16.73 to $18.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vertex Pharmaceuticals is 29.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.33.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vertex Pharmaceuticals is 29.09, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.22.

Price to Earnings Growth Ratio

Vertex Pharmaceuticals has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Vertex Pharmaceuticals has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.78% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 4.24.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently decreased by 4.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vertex Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vertex Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.67

News Sentiment

Vertex Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Vertex Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 29 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

33 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 136% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vertex Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/18/2026
• American Society of Nephrology (ASN) Kidney Week 2026: 10/23/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRTX
• CIK: 875320
• Web: www.vrtx.com
• Phone: (617) 341-6100
• Fax: 617-576-2109
• Employees: 6,400
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vertex Pharmaceuticals: $579.81
• High Price Target: $665.00
• Low Price Target: $442.00
• Potential Upside/Downside: +16.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 28 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.18
• Trailing P/E Ratio: 29.09
• Forward P/E Ratio: 29.87
• P/E Growth: 2.4
• Net Income: $3.95 billion
• Net Margins: 35.00%
• Pretax Margin: 41.90%
• Return on Equity: 23.09%
• Return on Assets: 16.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.19
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $12.59 billion
• Price / Sales: 10.08
• Cash Flow: $17.58 per share
• Price / Cash Flow: 28.43
• Book Value: $73.57 per share
• Price / Book: 6.79

Miscellaneous

• Outstanding Shares: 253,805,000
• Free Float: 253,297,000
• Market Cap: $126.84 billion
• Optionable: Optionable
• Beta: 0.28